文献速递白血病造血干细胞移植与细胞治疗

遗传学与MRD指导成人Ph阴性急性淋巴细胞白血病治疗分配

Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2026-01-01

该研究基于436例成人Ph阴性ALL患者,采用中心评估的MRD和遗传学进行风险分层,将高遗传风险、需2周期诱导达CR或诱导结束MRD≥0.01%者分配至allo-HSCT,其余接受化疗。3年OS概率64%,无HGR且MRD<0.01%者OS为81%,HGR且MRD阴性者为50%。遗传学联合MRD可准确识别适合移植或化疗的患者。

要点

  • 高危遗传学、需2周期诱导达CR或EOI MRD≥0.01%者应接受allo-HSCT。
  • 无HGR且EOI MRD<0.01%者3年OS达81%,可考虑化疗。
  • HGR且MRD阴性者3年OS仅50%,仍属高危。

核心结论

  • 遗传学联合MRD可准确识别成人Ph阴性ALL中适合allo-HSCT或化疗的患者。

研究设计与样本

  • 研究纳入436例成人Ph阴性ALL患者,中位年龄39岁(范围18-60),其中B-ALL 332例、T-ALL 104例。
  • 采用中心评估的MRD和遗传学进行风险分层,按意向治疗分配allo-HSCT或化疗。

主要发现

  • 243例非ETP-ALL患者(61%)分配至allo-HSCT,157例(39%)分配至化疗。
  • 3年OS概率为64%(95%CI 58-69)。
  • 无HGR且EOI MRD<0.01%者(n=109)3年OS为81%(95%CI 70-89),HGR且MRD阴性者(n=64)为50%(95%CI 34-63)。
  • ETP-ALL患者3年OS概率为61%(95%CI 37-79)。

关键数值与推荐

  • HGR(B-ALL)包括KMT2A重排、低超二倍体、年龄>35岁、TP53纯合突变/缺失或IKZF1与CDKN2A/B伴随缺失。
  • HGR(T-ALL)包括无NOTCH1/FBXW7突变和/或K/NRAS或PTEN改变。
  • 需2周期诱导达CR或EOI MRD≥0.01%者分配至allo-HSCT。
  • ETP-ALL接受不同诱导方案且均分配至allo-HSCT。

临床怎么用

  • 对成人Ph阴性ALL应中心评估遗传学和MRD以指导移植或化疗决策。
  • 无HGR且EOI MRD<0.01%者可考虑延迟巩固和维持化疗。
  • HGR且MRD阴性者仍应积极考虑allo-HSCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) genetic risk is usually combined with measurable residual disease (MRD) assignment to consolidation therapy. However, this combination is not uniform across trials and centralized assessment is not always performed. This study analyzed patient outcomes using centrally assessed MRD and genetics. Patients with high genetic risk (HGR), those who required 2 induction cycles for complete remission (CR), and patients with CR with end-of-induction (EOI) MRD of ≥0.01% were assigned to allogeneic hematopoietic stem cell transplant (allo-HSCT), whereas the remaining patients were assigned to delayed consolidation and maintenance. HGR for B-cell ALL included KMT2A rearrangements, low hypodiploidy and age of >35 years, homozygous TP53 mutations/deletions, or concomitant IKZF1 and CDKN2A/B deletions. HGR in T-cell ALL (T-ALL) included absence of NOTCH1/FBXW7 mutations and/or K/NRAS or PTEN alterations. Patients with early T-cell precursor (ETP) ALL received a different induction regimen, and all were assigned to allo-HSCT. Median age of 436 patients was 39 years (range, 18-60), 332 with B-lineage ALL and 104 with T-ALL. By intention to treat, 243 patients without ETP ALL (61%) were assigned to allo-HSCT and 157 (39%) to chemotherapy. The 3-year overall survival (OS) probability was 64% (95% confidence interval [CI], 58-69). For patients with CR and EOI MRD of <0.01% without HGR (n = 109), the OS probability was 81% (95% CI, 70-89), compared with 50% (95% CI, 34-63) for MRD-negative patients with HGR (n = 64). In patients with ETP ALL, the probability of 3-year OS was 61% (95% CI, 37-79). The combination of genetics and MRD allows accurate identification of adult patients with Ph- ALL who are candidates for allo-HSCT or chemotherapy. This trial was registered at www.clinicaltrials.gov as NCT04179929.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ribera JM, Torrent A, Morgades M, et al. Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2026. PMID: 42081455. doi:10.1182/blood.2025032645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。